Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1240

1.

Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro.

Nielsen MC, Andersen MN, Møller HJ.

Immunology. 2019 Oct 1. doi: 10.1111/imm.13125. [Epub ahead of print]

PMID:
31573680
2.

Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.

Laursen TL, Siggaard CB, Kazankov K, Sandahl TD, Møller HJ, Tarp B, Kristensen LH, Laursen AL, Leutscher P, Grønbaek H.

J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13204. [Epub ahead of print]

PMID:
31502741
3.

What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial.

Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Spellmann I, Musil R, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2019 Aug 28. doi: 10.1007/s00406-019-01055-4. [Epub ahead of print]

PMID:
31463563
4.

Alterations in Blood Monocyte Functions in Parkinson's Disease.

Nissen SK, Shrivastava K, Schulte C, Otzen DE, Goldeck D, Berg D, Møller HJ, Maetzler W, Romero-Ramos M.

Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27815. [Epub ahead of print]

PMID:
31449711
5.

The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT.

De Vlieger G, Vanhorebeek I, Wouters PJ, Derese I, Casaer MP, Debaveye Y, Hermans G, Meersseman P, Møller HJ, Van den Berghe G, Ingels C.

Crit Care. 2019 Aug 2;23(1):270. doi: 10.1186/s13054-019-2549-8.

6.

The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

Thomsen KL, Robertson FP, Holland-Fischer P, Davidson BR, Mookerjee RP, Møller HJ, Jalan R, Grønbæk H.

J Clin Exp Hepatol. 2019 May-Jun;9(3):302-311. doi: 10.1016/j.jceh.2018.09.006. Epub 2018 Oct 5.

PMID:
31360022
7.

Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.

Brock C, Hansen CS, Karmisholt J, Møller HJ, Juhl A, Farmer AD, Drewes AM, Riahi S, Lervang HH, Jakobsen PE, Brock B.

Br J Clin Pharmacol. 2019 Jul 24. doi: 10.1111/bcp.14063. [Epub ahead of print]

PMID:
31338868
8.

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.

Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Grønbæk H, Møller HJ, Vilstrup H, Steensberg A, Jeppesen PB.

EBioMedicine. 2019 Aug;46:444-451. doi: 10.1016/j.ebiom.2019.07.016. Epub 2019 Jul 17.

9.

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.

Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E.

J Hepatol. 2019 Jul 10. pii: S0168-8278(19)30404-0. doi: 10.1016/j.jhep.2019.06.031. [Epub ahead of print]

PMID:
31301321
10.

The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms.

Nielsen MC, Andersen MN, Rittig N, Rødgaard-Hansen S, Grønbaek H, Moestrup SK, Møller HJ, Etzerodt A.

J Leukoc Biol. 2019 Jun 26. doi: 10.1002/JLB.3A1218-500R. [Epub ahead of print]

PMID:
31242338
11.

Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study).

Knorr S, Bytoft B, Lohse Z, Boisen AB, Clausen TD, Jensen RB, Damm P, Beck-Nielsen H, Holst JJ, Hartmann B, Møller HJ, Højlund K, Gravholt CH, Jensen DM.

Diabetes Care. 2019 Aug;42(8):1560-1568. doi: 10.2337/dc19-0571. Epub 2019 Jun 4.

PMID:
31167890
12.

Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression.

Schennach R, Obermeier M, Spellmann I, Seemüller F, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M.

Schizophr Res. 2019 Jul;209:185-192. doi: 10.1016/j.schres.2019.04.022. Epub 2019 May 25.

PMID:
31138482
13.

Targeted lipid nanoparticle delivery of calcitriol to human monocyte-derived macrophages in vitro and in vivo: investigation of the anti-inflammatory effects of calcitriol.

Rafique A, Etzerodt A, Graversen JH, Moestrup SK, Dagnæs-Hansen F, Møller HJ.

Int J Nanomedicine. 2019 Apr 23;14:2829-2846. doi: 10.2147/IJN.S192113. eCollection 2019.

14.

Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose.

Siggaard CB, Kazankov K, Rødgaard-Hansen S, Møller HJ, Donnelly MC, Simpson KJ, Grønbaek H.

Scand J Gastroenterol. 2019 May;54(5):623-632. doi: 10.1080/00365521.2019.1608292. Epub 2019 May 8.

PMID:
31067143
15.

25(OH)D3 and 1.25(OH)2D3 inhibits TNF-α expression in human monocyte derived macrophages.

Rafique A, Rejnmark L, Heickendorff L, Møller HJ.

PLoS One. 2019 Apr 12;14(4):e0215383. doi: 10.1371/journal.pone.0215383. eCollection 2019.

16.

Validating registry data on statins prescriptions by blood measurements.

Riis AH, Erichsen R, Ostenfeld EB, Højskov CS, Thorlacius-Ussing O, Stender MT, Lash TL, Møller HJ.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):609-615. doi: 10.1002/pds.4700. Epub 2019 Feb 19.

PMID:
30779395
17.

Systemic, but not local, low-grade endotoxinemia increases plasma sCD163 independently of the cortisol response.

Bach E, Møller N, Jørgensen JOL, Buhl M, Møller HJ.

Endocr Connect. 2019 Feb 1;8(2):95-99. doi: 10.1530/EC-18-0554.

18.

STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes.

Andersen MN, Etzerodt A, Graversen JH, Holthof LC, Moestrup SK, Hokland M, Møller HJ.

Cancer Immunol Immunother. 2019 Mar;68(3):489-502. doi: 10.1007/s00262-019-02301-3. Epub 2019 Jan 14.

PMID:
30637473
19.

Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study.

Kambeitz-Ilankovic L, Haas SS, Meisenzahl E, Dwyer DB, Weiske J, Peters H, Möller HJ, Falkai P, Koutsouleris N.

Neuroimage Clin. 2019;21:101624. doi: 10.1016/j.nicl.2018.101624. Epub 2018 Dec 3.

20.

WFSBP guidelines on how to grade treatment evidence for clinical guideline development.

Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S; WFSBP Guideline Task Force Chairs.

World J Biol Psychiatry. 2019 Jan;20(1):2-16. doi: 10.1080/15622975.2018.1557346. Epub 2019 Feb 4. Review.

PMID:
30526182
21.

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H.

Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159. doi: 10.1038/s41575-018-0082-x. Review.

PMID:
30482910
22.

Possibilities and limitations of DSM-5 in improving the classification and diagnosis of mental disorders.

Möller HJ.

Psychiatr Pol. 2018 Aug 24;52(4):611-628. doi: 10.12740/PP/91040. Epub 2018 Aug 24. English, Polish.

23.

EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH).

Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll CU, De Hert M, Gaughran F, Schneider F, Kinnafick F, Falkai P, Möller HJ, Kahl KG.

Eur Psychiatry. 2018 Oct;54:124-144. doi: 10.1016/j.eurpsy.2018.07.004. Review.

PMID:
30257806
24.

High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study.

Björklund J, Laursen TL, Sandahl TD, Møller HJ, Vilstrup H, Ott P, Grønbæk H.

Orphanet J Rare Dis. 2018 Sep 21;13(1):169. doi: 10.1186/s13023-018-0910-7.

25.

Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.

Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ.

Pharmacopsychiatry. 2019 Jul;52(4):180-185. doi: 10.1055/a-0669-9461. Epub 2018 Sep 20.

PMID:
30235496
26.

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.

Kimer N, Gudmann NS, Pedersen JS, Møller S, Nielsen MJ, Leeming DJ, Karsdal MA, Møller HJ, Bendtsen F, Grønbæk H.

PLoS One. 2018 Sep 5;13(9):e0203200. doi: 10.1371/journal.pone.0203200. eCollection 2018.

27.

Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis.

Heftdal LD, Loft AG, Hendricks O, Ashouri Christiansen A, Schiøttz-Christensen B, Arnbak B, Jurik AG, Østgård R, Winding Deleuran B, Møller HJ, Greisen SR.

Scand J Clin Lab Invest. 2018 Oct;78(6):483-489. doi: 10.1080/00365513.2018.1500704. Epub 2018 Sep 4.

PMID:
30176763
28.

Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.

Kazankov K, Alisi A, Møller HJ, De Vito R, Rittig S, Mahler B, Nobili V, Grønbæk H.

J Pediatr Gastroenterol Nutr. 2018 Nov;67(5):635-642. doi: 10.1097/MPG.0000000000002111.

PMID:
30074574
29.

Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives?

Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2018 Sep;268(6):525-527. doi: 10.1007/s00406-018-0926-y. No abstract available.

PMID:
30056559
30.

Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.

Lund Laursen T, Brøckner Siggard C, Kazankov K, Damgaard Sandahl T, Møller HJ, Ong A, Douglas MW, George J, Tarp B, Hagelskjaer Kristensen L, Lund Laursen A, Hiramatsu A, Nakahara T, Chayama K, Grønbaek H.

Scand J Gastroenterol. 2018 Aug;53(8):986-993. doi: 10.1080/00365521.2018.1481996. Epub 2018 Jul 10.

PMID:
29987961
31.

Efficacy of extended clinical management, group CBT, and group plus individual CBT for major depression: Results of a two-year follow-up study.

Schaub A, Goldmann U, Mueser TK, Goerigk S, Hautzinger M, Roth E, Charypar M, Engel R, Möller HJ.

J Affect Disord. 2018 Oct 1;238:570-578. doi: 10.1016/j.jad.2018.05.081. Epub 2018 Jun 13.

PMID:
29940521
32.

Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project.

Stübner S, Grohmann R, Greil W, Zhang X, Müller-Oerlinghausen B, Bleich S, Rüther E, Möller HJ, Engel R, Falkai P, Toto S, Kasper S, Neyazi A.

Int J Neuropsychopharmacol. 2018 Sep 1;21(9):814-821. doi: 10.1093/ijnp/pyy048.

33.

Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis.

Svart M, Rittig N, Møller N, Møller HJ, Gronbaek H.

J Diabetes Investig. 2019 Jan;10(1):67-72. doi: 10.1111/jdi.12869. Epub 2018 Jun 30.

34.

Soluble Macrophage Mannose Receptor (sCD206/sMR) as a Biomarker in Human Immunodeficiency Virus Infection.

Andersen MN, Hønge BL, Jespersen S, Medina C, da Silva Té D, Laursen A, Wejse C, Erikstrup C, Møller HJ; Bissau HIV Cohort Study Group.

J Infect Dis. 2018 Sep 8;218(8):1291-1295. doi: 10.1093/infdis/jiy318.

PMID:
29800140
35.

Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1 year after their first in-patient treatment.

Zäske H, Linden M, Degner D, Jockers-Scherübl M, Klingberg S, Klosterkötter J, Maier W, Möller HJ, Sauer H, Schmitt A, Gaebel W.

Eur Arch Psychiatry Clin Neurosci. 2019 Jun;269(4):459-468. doi: 10.1007/s00406-018-0892-4. Epub 2018 Apr 25.

PMID:
29696357
36.

Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.

Musil R, Seemüller F, Meyer S, Spellmann I, Adli M, Bauer M, Kronmüller KT, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller HJ, Riedel M.

Int J Methods Psychiatr Res. 2018 Mar;27(1). doi: 10.1002/mpr.1569. Epub 2017 Jun 14.

PMID:
29498147
37.

QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.

Spellmann I, Reinhard MA, Veverka D, Zill P, Obermeier M, Dehning S, Schennach R, Müller N, Möller HJ, Riedel M, Musil R.

Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):383-390. doi: 10.1007/s00406-018-0880-8. Epub 2018 Feb 10.

PMID:
29429138
38.

The macrophage activation marker sMR as a diagnostic and prognostic marker in patients with acute infectious disease with or without sepsis.

Marie Relster M, Gaini S, Møller HJ, Johansen IS, Pedersen C.

Scand J Clin Lab Invest. 2018 May;78(3):180-186. doi: 10.1080/00365513.2018.1431841. Epub 2018 Jan 31.

PMID:
29383956
39.

Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis.

Gjelstrup MC, Stilund M, Petersen T, Møller HJ, Petersen EL, Christensen T.

Immunol Cell Biol. 2018 Feb;96(2):160-174. doi: 10.1111/imcb.1025. Epub 2017 Dec 11.

40.

Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial.

Rittig N, Svart M, Jessen N, Møller N, Møller HJ, Grønbæk H.

Endocr Connect. 2018 Jan;7(1):107-114. doi: 10.1530/EC-17-0296.

41.

Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.

Rainer F, Horvath A, Sandahl TD, Leber B, Schmerboeck B, Blesl A, Groselj-Strele A, Stauber RE, Fickert P, Stiegler P, Møller HJ, Grønbaek H, Stadlbauer V.

Aliment Pharmacol Ther. 2018 Mar;47(5):657-664. doi: 10.1111/apt.14474. Epub 2017 Dec 21.

42.

A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3).

Ricken R, Wiethoff K, Reinhold T, Stamm TJ, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Laux G, Hauth I, Möller HJ, Heinz A, Bauer M, Adli M.

J Affect Disord. 2018 Mar 1;228:173-177. doi: 10.1016/j.jad.2017.11.051. Epub 2017 Nov 13.

PMID:
29253683
43.

The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.

Sandahl TD, Støy SH, Laursen TL, Rødgaard-Hansen S, Møller HJ, Møller S, Vilstrup H, Grønbæk H.

PLoS One. 2017 Dec 13;12(12):e0189345. doi: 10.1371/journal.pone.0189345. eCollection 2017.

44.

Correction to: Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort.

Deichgræber P, Witte DR, Møller HJ, Skriver MV, Richelsen B, Jørgensen ME, Johansen NB, Sandbæk A.

Diabetologia. 2018 Feb;61(2):498-503. doi: 10.1007/s00125-017-4498-6.

PMID:
29204667
45.

Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.

Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S.

Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):183-193. doi: 10.1007/s00406-017-0852-4. Epub 2017 Nov 17.

46.

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder.

Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov S, Möller HJ, Kasper S; Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic.

World J Biol Psychiatry. 2018 Feb;19(1):2-58. doi: 10.1080/15622975.2017.1384850. Epub 2017 Nov 3. Review.

PMID:
29098925
47.

New aspects of the vulnerability stress model in general, its relevance in schizophrenic psychoses and the place of antipsychotics.

Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2017 Sep;267(6):485-486. doi: 10.1007/s00406-017-0825-7. No abstract available.

PMID:
28725951
48.

Letter: autoimmune hepatitis-drug-induced liver injury must always be excluded. Authors' reply.

Grønbaek H, Møller HJ, Vilstrup H.

Aliment Pharmacol Ther. 2017 Aug;46(3):384. doi: 10.1111/apt.14181. No abstract available. Erratum in: Aliment Pharmacol Ther. 2018 Jan;47(1):157.

49.

Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis.

Wessels H, Wagner M, Kuhr K, Berning J, Pützfeld V, Janssen B, Bottlender R, Maurer K, Möller HJ, Gaebel W, Häfner H, Maier W, Klosterkötter J, Bechdolf A.

Early Interv Psychiatry. 2019 Feb;13(1):120-127. doi: 10.1111/eip.12460. Epub 2017 Jul 4.

PMID:
28675695
50.

How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial.

Adli M, Wiethoff K, Baghai TC, Fisher R, Seemüller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Kronmüller KT, Smolka MN, Schlattmann P, Berger M, Ricken R, Stamm TJ, Heinz A, Bauer M.

Int J Neuropsychopharmacol. 2017 Sep 1;20(9):721-730. doi: 10.1093/ijnp/pyx043.

Supplemental Content

Loading ...
Support Center